The body has a natural cellular recycling machinery known as the ubiquitin proteasome system that breaks down unwanted proteins. Kymera Therapeutics has developed a drug discovery platform that exploits this natural biologic process to target disease-causing proteins that had been previously considered undruggable using small molecule therapies. We spoke to Nello Mainolfi, co-founder, president, and CEO of Kymera, about the company’s discovery platform, how it exploits a natural housecleaning mechanism within the body, and why this approach could enable the targeting of proteins that previously had been considered beyond the reach of small molecule therapies.
view more